Advertisement
Advertisement
U.S. Markets close in 3 hrs 45 mins
Advertisement
Advertisement
Advertisement
Advertisement

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0200-0.0400 (-1.94%)
As of 12:14PM EDT. Market open.
Advertisement
Full screen
Loading interactive chart...
  • American City Business Journals

    As monkeypox spreads, Durham firm getting plenty of attention

    A Durham company's smallpox treatment may be beneficial against monkeypox, according to the CDC. And it appears to be in high demand.

  • Reuters

    Chimerix gets up to $25.3 mln contract from Canada for smallpox drug

    Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads across the world. There have been more than 3,200 confirmed cases of monkeypox and one death reported in the last six weeks from 48 countries where it does not usually spread, according to the World Health Organization. The contract, awarded by the Public Health Agency of Canada, comes a day after Chimerix announced an order worth $9.3 million for the smallpox drug, Tembexa.

  • GlobeNewswire

    Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada

    DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the

Advertisement
Advertisement